Digital Biomarkers in Parkinson's Disease: Missing the Forest for the Trees?
作者信息
Jha Ashwani, Espay Alberto J, Lees Andrew J
机构信息
UCL Queen Square Institute of Neurology London United Kingdom.
James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology University of Cincinnati Cincinnati Ohio USA.
出版信息
Mov Disord Clin Pract. 2023 May 17;10(Suppl 2):S68-S72. doi: 10.1002/mdc3.13746. eCollection 2023 Aug.
Abstract
摘要
相似文献
1
Digital Biomarkers in Parkinson's Disease: Missing the Forest for the Trees?
Mov Disord Clin Pract. 2023 May 17;10(Suppl 2):S68-S72. doi: 10.1002/mdc3.13746. eCollection 2023 Aug.
2
Predictors of rapid eye movement sleep behavior disorder in patients with Parkinson's disease based on random forest and decision tree.
PLoS One. 2022 Jun 16;17(6):e0269392. doi: 10.1371/journal.pone.0269392. eCollection 2022.
3
Digital Biomarkers of Mobility in Parkinson's Disease During Daily Living.
J Parkinsons Dis. 2020;10(3):1099-1111. doi: 10.3233/JPD-201914.
4
Improved measurement of disease progression in people living with early Parkinson's disease using digital health technologies.
Commun Med (Lond). 2024 Mar 15;4(1):49. doi: 10.1038/s43856-024-00481-3.
5
The Facilitators and Barriers to Digital Health for Managing Nutrition in People With Parkinson's Disease and Their Caregivers: A Formative, Qualitative Study.
J Nutr Educ Behav. 2023 Aug;55(8):553-563. doi: 10.1016/j.jneb.2023.05.252.
6
Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid.
Brain Commun. 2022 Dec 28;5(1):fcac343. doi: 10.1093/braincomms/fcac343. eCollection 2023.
7
Is the Random Forest Algorithm Suitable for Predicting Parkinson's Disease with Mild Cognitive Impairment out of Parkinson's Disease with Normal Cognition?
Int J Environ Res Public Health. 2020 Apr 10;17(7):2594. doi: 10.3390/ijerph17072594.
8
Digital Health Technology to Measure Drug Efficacy in Clinical Trials for Parkinson's Disease: A Regulatory Perspective.
J Parkinsons Dis. 2021;11(s1):S111-S115. doi: 10.3233/JPD-202416.
9
Symptoms and medications change patterns for Parkinson's disease patients stratification.
Artif Intell Med. 2018 Sep;91:82-95. doi: 10.1016/j.artmed.2018.04.010. Epub 2018 May 24.
10
Can detection and prediction models for Alzheimer's Disease be applied to Prodromal Parkinson's Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures.
Open Res Eur. 2022 Jan 10;1:146. doi: 10.12688/openreseurope.14216.2. eCollection 2021.
引用本文的文献
1
Digital Biomarkers for Parkinson Disease: Bibliometric Analysis and a Scoping Review of Deep Learning for Freezing of Gait.
J Med Internet Res. 2025 May 20;27:e71560. doi: 10.2196/71560.
2
Machine Learning and Digital Biomarkers Can Detect Early Stages of Neurodegenerative Diseases.
Sensors (Basel). 2024 Feb 29;24(5):1572. doi: 10.3390/s24051572.
3
Unmet Needs in Parkinson's Disease.
Mov Disord Clin Pract. 2023 Aug 23;10(Suppl 2):S47-S49. doi: 10.1002/mdc3.13838. eCollection 2023 Aug.
本文引用的文献
1
Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease.
Sci Rep. 2022 Jul 15;12(1):12081. doi: 10.1038/s41598-022-15874-4.
2
Identifying and characterising sources of variability in digital outcome measures in Parkinson's disease.
NPJ Digit Med. 2022 Jul 15;5(1):93. doi: 10.1038/s41746-022-00643-4.
3
A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson's disease.
J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):617-624. doi: 10.1136/jnnp-2021-327880. Epub 2022 Apr 6.
4
Remote smartphone monitoring of Parkinson's disease and individual response to therapy.
Nat Biotechnol. 2022 Apr;40(4):480-487. doi: 10.1038/s41587-021-00974-9. Epub 2021 Aug 9.
5
Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective.
J Parkinsons Dis. 2021;11(s1):S103-S109. doi: 10.3233/JPD-202428.
6
Smartwatch inertial sensors continuously monitor real-world motor fluctuations in Parkinson's disease.
Sci Transl Med. 2021 Feb 3;13(579). doi: 10.1126/scitranslmed.abd7865.
7
A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach.
Digit Biomark. 2020 Nov 26;4(Suppl 1):13-27. doi: 10.1159/000512513. eCollection 2020 Winter.
8
A blinded, controlled trial of objective measurement in Parkinson's disease.
NPJ Parkinsons Dis. 2020 Nov 20;6(1):35. doi: 10.1038/s41531-020-00136-9.
9
The CloudUPDRS smartphone software in Parkinson's study: cross-validation against blinded human raters.
NPJ Parkinsons Dis. 2020 Dec 8;6(1):36. doi: 10.1038/s41531-020-00135-w.
10
Digital Measures That Matter to Patients: A Framework to Guide the Selection and Development of Digital Measures of Health.
Digit Biomark. 2020 Sep 15;4(3):69-77. doi: 10.1159/000509725. eCollection 2020 Sep-Dec.
Zotero 插件